ABL1 and Alzheimer disease: Altogether, our results have shown a positive effect of the allosteric inhibitor for c-Abl, neurotinib, over the AD pathology displayed by aged 22-month-old APP/PS1 mice, further validating c-Abl as a key player in the development of AD pathology and cognitive impairment of AD.